title: 3,4-Methylenedioxypyrovalerone prevents while methylone enhances methamphetamine-induced damage to dopamine nerve endings: β-ketoamphetamine modulation of neurotoxicity by the dopamine transporter.
abstract: Methylone, 3,4-methylenedioxypyrovalerone (MDPV), and mephedrone are psychoactive ingredients of 'bath salts' and their abuse represents a growing public health care concern. These drugs are cathinone derivatives and are classified chemically as β-ketoamphetamines. Because of their close structural similarity to the amphetamines, methylone, MDPV, and mephedrone share most of their pharmacological, neurochemical, and behavioral properties. One point of divergence in their actions is the ability to cause damage to the CNS. Unlike methamphetamine, the β-ketoamphetamines do not damage dopamine (DA) nerve endings. However, mephedrone has been shown to significantly accentuate methamphetamine neurotoxicity. Bath salt formulations contain numerous different psychoactive ingredients, and individuals who abuse bath salts also coabuse other illicit drugs. Therefore, we have evaluated the effects of methylone, MDPV, mephedrone, and methamphetamine on DA nerve endings. The β-ketoamphetamines alone or in all possible two-drug combinations do not result in damage to DA nerve endings but do cause hyperthermia. MDPV completely protects against the neurotoxic effects of methamphetamine while methylone accentuates it. Neither MDPV nor methylone attenuates the hyperthermic effects of methamphetamine. The potent neuroprotective effects of MDPV extend to amphetamine-, 3,4-methylenedioxymethamphetamine-, and MPTP-induced neurotoxicity. These results indicate that β-ketoamphetamine drugs that are non-substrate blockers of the DA transporter (i.e., MDPV) protect against methamphetamine neurotoxicity, whereas those that are substrates for uptake by the DA transporter and which cause DA release (i.e., methylone, mephedrone) accentuate neurotoxicity. METH (a) enters DA nerve endings via the DAT, causes leakage of DA into the cytoplasm and then into the synapse via DAT-mediated reverse transport. Methylone (METHY) and mephedrone (MEPH; b), like METH, are substrates for the DAT but release DA from cytoplasmic pools selectively. When METH is combined with METHY or MEPH (c), DA efflux and neurotoxicity are enhanced. MDPV (d), which is a non-substrate blocker of the DAT, prevents METH uptake and efflux of DA. Therefore, bath salts that are substrates for the DAT and release DA (METHY, MEPH) accentuate METH neurotoxicity, whereas those that are non-substrate blockers of the DAT (MDPV) are neuroprotective.
authors: Research & Development Service, John D. Dingell VA Medical Center, Detroit, Michigan, USA; Department of Psychiatry & Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA.
authors: John H
authors: JH
authors: Anneken
authors: Mariana
authors: M
authors: Angoa-Pérez
authors: Donald M
authors: DM
authors: Kuhn
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D000818:Animals; D052117:Benzodioxoles / Q000494:pharmacology*; D001831:Body Temperature / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000633:toxicity*; D003342:Corpus Striatum / Q000166:cytology* / Q000187:drug effects; D004298:Dopamine / Q000378:metabolism*; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D008694:Methamphetamine / Q000031:analogs & derivatives* / Q000633:toxicity*; D051379:Mice; D008810:Mice, Inbred C57BL; D009411:Nerve Endings / Q000187:drug effects*; D009498:Neurotoxins / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D000094982:Synthetic Cathinone
chemical_list: D052117:Benzodioxoles; D000697:Central Nervous System Stimulants; D050483:Dopamine Plasma Membrane Transport Proteins; D005904:Glial Fibrillary Acidic Protein; D009498:Neurotoxins; D011619:Psychotropic Drugs; D011759:Pyrrolidines; D008694:Methamphetamine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D014446:Tyrosine 3-Monooxygenase; C400939:methylone; D004298:Dopamine; D000094982:Synthetic Cathinone
keywords: dopamine nerve ending; dopamine transporter; neurotoxic amphetamines; neurotoxicity; β-ketoamphetamines
references: Br J Pharmacol. 2013 Jan;168(2):458-70
references: 22897747
references: Toxicol Lett. 2012 Jan 5;208(1):12-5
references: 22008731
references: J Psychoactive Drugs. 2014 Apr-Jun;46(2):147-53
references: 25052791
references: Addict Biol. 2014 Mar;19(2):165-74
references: 22784198
references: Br J Pharmacol. 2013 Feb;168(4):966-77
references: 23043631
references: Br J Pharmacol. 2012 Sep;167(2):407-20
references: 22509960
references: Toxicol Sci. 2014 Sep;141(1):120-31
references: 24913801
references: BMC Res Notes. 2013;6:220
references: 23734766
references: Neurochem Int. 1987;11(4):463-75
references: 20501194
references: Br J Pharmacol. 2011 Dec;164(8):1949-58
references: 21615721
references: Mol Pharmacol. 1995 Feb;47(2):368-73
references: 7870046
references: Addict Biol. 2012 Mar;17(2):409-22
references: 21995495
references: Eur Neuropsychopharmacol. 2013 Sep;23(9):1085-95
references: 23051939
references: Life Sci. 2014 Feb 27;97(1):31-6
references: 23892197
references: J Neurochem. 2008 May;105(3):605-16
references: 18088364
references: Eur J Pharmacol. 1985 Feb 12;109(1):73-80
references: 2581794
references: Psychopharmacology (Berl). 2014 Jan;231(1):199-207
references: 23949206
references: J Pharmacol Exp Ther. 2011 Nov;339(2):530-6
references: 21810934
references: Psychopharmacology (Berl). 2013 Feb;225(3):675-85
references: 22972412
references: Psychopharmacology (Berl). 2013 Jun;227(3):493-9
references: 23371489
references: Drug Alcohol Depend. 2013 Dec 1;133(2):746-50
references: 23890492
references: J Neuroimmune Pharmacol. 2012 Dec;7(4):951-68
references: 22833424
references: Clin Toxicol (Phila). 2011 Jul;49(6):499-505
references: 21824061
references: Neuropsychopharmacology. 2008 Apr;33(5):1162-70
references: 17581531
references: Pharmacol Biochem Behav. 2013 Jan;103(3):501-9
references: 23099177
references: Drug Alcohol Depend. 2012 Nov 1;126(1-2):257-62
references: 22652295
references: Life Sci. 2014 Feb 27;97(1):37-44
references: 23892199
references: Neuropsychopharmacology. 2013 Mar;38(4):563-73
references: 23212455
references: Behav Brain Res. 2012 Sep 1;234(1):76-81
references: 22728726
references: Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):411-6
references: 24739011
references: Psychopharmacology (Berl). 2014 Aug;231(16):3119-29
references: 24705904
references: Drug Alcohol Depend. 2013 Sep 1;132(1-2):1-12
references: 23916320
references: Neurotoxicology. 2012 Oct;33(5):1305-13
references: 22922498
references: Drug Alcohol Depend. 2008 Aug 1;96(3):222-32
references: 18468815
references: Neuropsychopharmacology. 2013 Mar;38(4):552-62
references: 23072836
references: Biochem Pharmacol. 2013 Jun 15;85(12):1803-15
references: 23583454
references: Neuropsychopharmacology. 2012 Apr;37(5):1192-203
references: 22169943
references: J Neurochem. 2013 Apr;125(1):102-10
references: 23205838
references: Addiction. 2011 Nov;106(11):1991-6
references: 21592252
references: ACS Chem Neurosci. 2013 Dec 18;4(12):1524-9
references: 24116392
references: PLoS One. 2014;9(6):e99002
references: 24892744
references: Clin Toxicol (Phila). 2011 Oct;49(8):705-19
references: 21970769
references: J Neurochem. 1993 May;60(5):1792-9
references: 8473897
references: PLoS One. 2012;7(8):e44652
references: 22952999
references: Br J Pharmacol. 2013 Apr;168(7):1750-7
references: 23170765
references: Brain Res. 1994 Jun 27;649(1-2):217-24
references: 7953636
references: Proc Natl Acad Sci U S A. 1985 Apr;82(7):2173-7
references: 3872460
references: Prog Neurobiol. 2005 Apr;75(6):406-33
references: 15955613
references: Am J Psychiatry. 2007 Jan;164(1):160-2
references: 17202560
references: Drug Alcohol Depend. 2012 Nov 1;126(1-2):168-75
references: 22664136
references: J Neurochem. 2009 Jun;109(6):1745-55
references: 19457119
references: Drug Alcohol Depend. 2013 Jan 1;127(1-3):248-53
references: 22832282
references: PLoS One. 2012;7(9):e45473
references: 23029034
references: Addict Biol. 2013 Sep;18(5):786-99
references: 23363010
references: J Neurochem. 2012 Mar;120(6):1097-107
references: 22191803
references: Behav Pharmacol. 2013 Sep;24(5-6):437-47
references: 23839026
references: Neuropharmacology. 2013 Aug;71:130-40
references: 23597511
references: Behav Pharmacol. 2013 Dec;24(8):684-8
references: 24126218
references: Neuropharmacology. 2014 Dec;87:206-13
references: 24594476